AngioDynamics, Inc.

NasdaqGS ANGO

AngioDynamics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending November 30, 2024: -19.16%

AngioDynamics, Inc. Return on Capital Employed (ROCE) is -19.16% for the Trailing 12 Months (TTM) ending November 30, 2024, a -96.65% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • AngioDynamics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending November 30, 2023 was -9.75%, a -60.18% change year over year.
  • AngioDynamics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending November 30, 2022 was -6.08%, a 28.54% change year over year.
  • AngioDynamics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending November 30, 2021 was -8.51%, a 71.15% change year over year.
  • AngioDynamics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending November 30, 2020 was -29.51%, a -3,675.31% change year over year.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
Loading...
NasdaqGS: ANGO

AngioDynamics, Inc.

CEO Mr. James C. Clemmer
IPO Date June 1, 2004
Location United States
Headquarters 14 Plaza Drive
Employees 748
Sector Health Care
Industries
Description

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

NVST

Envista Holdings Corp

USD 18.85

-0.74%

ATR

AptarGroup, Inc.

USD 154.61

0.47%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

ATRC

AtriCure, Inc.

USD 34.69

0.87%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

KRMD

KORU Medical Systems, Inc.

USD 4.07

3.04%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

AKYA

Akoya Biosciences, Inc.

USD 2.60

-11.26%

StockViz Staff

January 15, 2025

Any question? Send us an email